INT47942

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.70
First Reported 1994
Last Reported 2010
Negated 3
Speculated 0
Reported most in Abstract
Documents 38
Total Number 38
Disease Relevance 15.94
Pain Relevance 6.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Glp1r) signal transducer activity (Glp1r)
Anatomy Link Frequency
plasma 6
lateral 1
nerves 1
Glp1r (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 109 99.92 Very High Very High Very High
Somatostatin 21 99.92 Very High Very High Very High
substance P 12 99.76 Very High Very High Very High
tolerance 91 99.54 Very High Very High Very High
Central nervous system 170 99.50 Very High Very High Very High
qutenza 9 99.28 Very High Very High Very High
Clonidine 3 98.74 Very High Very High Very High
antagonist 31 98.40 Very High Very High Very High
amygdala 5 98.36 Very High Very High Very High
tetrodotoxin 6 96.80 Very High Very High Very High
Disease Link Frequency Relevance Heat
Aids-related Complex 265 100.00 Very High Very High Very High
Impaired Glucose Tolerance 94 99.68 Very High Very High Very High
Myocardial Infarction 522 99.60 Very High Very High Very High
Diabetes Mellitus 575 99.28 Very High Very High Very High
Hyperglycemia 62 99.00 Very High Very High Very High
Disease 91 98.52 Very High Very High Very High
Neurodegenerative Disease 14 98.52 Very High Very High Very High
Hyperlipidemia 22 98.48 Very High Very High Very High
Weight Loss 61 97.76 Very High Very High Very High
Appetite Loss 15 97.72 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Food ingestion induces a rapid increase in the insulinotropic glucagon-like peptide-1 (GLP-1) in plasma.
Positive_regulation (increase) of GLP-1 in plasma
1) Confidence 0.70 Published 1995 Journal J. Endocrinol. Section Abstract Doc Link 7490533 Disease Relevance 0 Pain Relevance 0.14
Finally, the muscarinic cholinergic agonist bethanechol at a concentration of 10(-4) M evoked a gradual increase in GLP-1 immunoreactivity, which reached a maximal value (900% over basal) at the end of the 30-min infusion period.
Positive_regulation (increase) of GLP-1 associated with agonist
2) Confidence 0.69 Published 1994 Journal Endocrinology Section Abstract Doc Link 7988423 Disease Relevance 0 Pain Relevance 0.42
Clonidine (10(-7) M), an alpha2-agonist, induced a moderate and delayed increase of GLP-1 and PYY but abolished the isoproterenol-induced peptide secretion.
Positive_regulation (increase) of GLP-1 associated with agonist and clonidine
3) Confidence 0.68 Published 1999 Journal J. Endocrinol. Section Abstract Doc Link 10425466 Disease Relevance 0 Pain Relevance 0.26
These observations have led these authors to suggest that stimulation of GLP-1 receptors (GLP-1R's) could be a therapeutic option in neurodegenerative disorders such as PD.
Positive_regulation (stimulation) of GLP-1 associated with disease and neurodegenerative disease
4) Confidence 0.64 Published 2008 Journal J Neuroinflammation Section Body Doc Link PMC2426681 Disease Relevance 1.10 Pain Relevance 0.12
Food ingestion induces a rapid increase in the insulinotropic glucagon-like peptide-1 (GLP-1) in plasma.
Positive_regulation (increase) of glucagon-like peptide-1 in plasma
5) Confidence 0.61 Published 1995 Journal J. Endocrinol. Section Abstract Doc Link 7490533 Disease Relevance 0 Pain Relevance 0.14
RESULTS¬óWe found that central, but not peripheral, administration of low doses of a GLP-1 receptor antagonist caused relative hyperglycemia during a glucose tolerance test, suggesting that activation of central GLP-1 receptors regulates key processes involved in the maintenance of glucose homeostasis.
Positive_regulation (activation) of GLP-1 associated with hyperglycemia, antagonist, tolerance and impaired glucose tolerance
6) Confidence 0.60 Published 2008 Journal Diabetes Section Abstract Doc Link PMC2494674 Disease Relevance 0.44 Pain Relevance 0.29
Further, since circulating GLP-1 is not increased during glucose tolerance tests, peripheral GLP-1 may not be the important source of GLP-1 activating the CNS receptors that regulate islet and hepatic function.
Neg (not) Positive_regulation (increased) of GLP-1 associated with tolerance, central nervous system and impaired glucose tolerance
7) Confidence 0.60 Published 2008 Journal Diabetes Section Body Doc Link PMC2494674 Disease Relevance 0.69 Pain Relevance 0.34
Furthermore, activation of the GLP-1 receptor was required upstream for stimulation of these pathways.
Positive_regulation (activation) of GLP-1 receptor
8) Confidence 0.59 Published 2010 Journal Cardiovasc Diabetol Section Body Doc Link PMC2996354 Disease Relevance 0.64 Pain Relevance 0
These observations have led these authors to suggest that stimulation of GLP-1 receptors (GLP-1R's) could be a therapeutic option in neurodegenerative disorders such as PD.
Positive_regulation (stimulation) of GLP-1R associated with disease and neurodegenerative disease
9) Confidence 0.55 Published 2008 Journal J Neuroinflammation Section Body Doc Link PMC2426681 Disease Relevance 1.11 Pain Relevance 0.12
Furthermore, vagal afferent nerves mediate the inhibitory action of GLP-1 on gastric motor function.
Positive_regulation (mediate) of GLP-1 in nerves
10) Confidence 0.50 Published 1997 Journal Am. J. Physiol. Section Abstract Doc Link 9357836 Disease Relevance 0.06 Pain Relevance 0.07
The lowest concentration of bethanechol used in the present study (10(-5) M) did not increase portal GLP-1 immunoreactivity over the basal value.
Neg (not) Positive_regulation (increase) of GLP-1
11) Confidence 0.50 Published 1994 Journal Endocrinology Section Abstract Doc Link 7988423 Disease Relevance 0 Pain Relevance 0.40
Because terbutaline but not dobutamine or BRL 37,344 (10(-5) M) induced significant GLP-1 and PYY secretions (135+/-30 and 305+/-39 fmol/8 min respectively), isoproterenol-induced secretions are suggested to result mainly from stimulation of the beta2-isoreceptor type.
Neg (not) Positive_regulation (induced) of GLP-1
12) Confidence 0.49 Published 1999 Journal J. Endocrinol. Section Abstract Doc Link 10425466 Disease Relevance 0 Pain Relevance 0.24
General stimulation of adrenergic receptors with epinephrine (10(-7) M) induced significant GLP-1 and PYY secretions (94+/-38 and 257+/-59 fmol/8 min respectively) which were abolished upon propranolol (10(-7) M) pretreatment and strongly decreased upon infusion with 10(-8) M prazosin.
Positive_regulation (induced) of GLP-1
13) Confidence 0.49 Published 1999 Journal J. Endocrinol. Section Abstract Doc Link 10425466 Disease Relevance 0 Pain Relevance 0.12
It was recently proposed that suitable succinic acid esters could be used to potentiate the insulinotropic action of glucagon-like peptide 1 (GLP-1) in the treatment of type-2 diabetes mellitus.
Positive_regulation (potentiate) of GLP-1 associated with diabetes mellitus
14) Confidence 0.47 Published 2001 Journal Int. J. Mol. Med. Section Abstract Doc Link 11494054 Disease Relevance 0.10 Pain Relevance 0
It was recently proposed that suitable succinic acid esters could be used to potentiate the insulinotropic action of glucagon-like peptide 1 (GLP-1) in the treatment of type-2 diabetes mellitus.
Positive_regulation (potentiate) of glucagon-like peptide 1 associated with diabetes mellitus
15) Confidence 0.47 Published 2001 Journal Int. J. Mol. Med. Section Abstract Doc Link 11494054 Disease Relevance 0.10 Pain Relevance 0
This model was responsive to insulin and GLP-1 analog, both of which were effective in ameliorating hyperglycemia.
Positive_regulation (responsive) of GLP-1 associated with hyperglycemia
16) Confidence 0.46 Published 2006 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 16280413 Disease Relevance 0.97 Pain Relevance 0.09
The duodenal, jejunal, and ileal administration of ZeinH induced dose-dependent increases in portal GLP-1 concentration.
Positive_regulation (increases) of GLP-1
17) Confidence 0.46 Published 2009 Journal Am. J. Physiol. Gastrointest. Liver Physiol. Section Abstract Doc Link 19661152 Disease Relevance 0 Pain Relevance 0.18
Thus, DMG indeed appears as a suitable tool to potentiate the insulinotropic action of GLP-1.
Positive_regulation (potentiate) of GLP-1
18) Confidence 0.44 Published 2001 Journal Int. J. Mol. Med. Section Abstract Doc Link 11605022 Disease Relevance 0.08 Pain Relevance 0
The following plasmids were used for probe synthesis: 1) for GLP-1 receptors, the full-length rat sequence including 83 bp of the 3?
Positive_regulation (including) of GLP-1
19) Confidence 0.44 Published 2008 Journal Diabetes Section Body Doc Link PMC2494674 Disease Relevance 0.25 Pain Relevance 0.03
This is because GLP-1 receptors in the central nucleus of the amygdala initiate visceral illness (16), and lateral and i3vt CNS administration of GLP-1 increases GLP-1 signaling in this nucleus and in brain areas that cause anorexia, indicating that GLP-1 receptors in specific nuclei have discrete effects.
Positive_regulation (increases) of GLP-1 in lateral associated with appetite loss, central nervous system and amygdala
20) Confidence 0.44 Published 2008 Journal Diabetes Section Body Doc Link PMC2494674 Disease Relevance 0.46 Pain Relevance 0.31

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox